Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery
Company Expands Product Pipeline in Neurodegenerative Arena
OCEANSIDE, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today successful production of a stable microemulsion of Alpha Lipoic Acid (ALA) from ingredients Generally Regarded as Safe (GRAS). The microemulsion, which is a form of racemic alpha lipoic acid containing microparticles of ALA, is an ingredient in the Company’s issued U.S. Patent No.: 9,682,047 along with pterostilbene, the active ingredient in the Company’s patented ProJuvenol product.
Like pterostilbene, ALA is a very potent anti-oxidant and is also known as -lipoic acid, alpha lipoic acid (ALA) and thioctic acid, an organosulfur compound derived from octanoic acid and appears to be an ideal substance in the treatment of oxidative brain and neural disorders involving free radical processes. Thiols like ALA are central to antioxidant defense in brain and other tissues.
It is believed that Reactive Oxygen Species (ROS) are involved in many different types of pathologic conditions in the brain and neural tissue. Brain disorders involving free radical injury have few neuropharmacological intervention strategies for treatment of these conditions. ALA as a potent antioxidant, can regenerate through redox cycling other potent antioxidants like vitamin C and vitamin E, and to raise intracellular glutathione levels. The most important thiol antioxidant, glutathione, cannot be directly administered, whereas alpha lipoic acid can.
“There are numerous publications showing promising effects of alpha lipoic acid in preclinical models of neurodegenerative conditions such as multiple sclerosis1,2, stroke3,4, and Alzheimer’s Disease5,” said James Veltmeyer, MD, Chief Medical Officer of Therapeutic Solutions International. “By providing alternative delivery mechanisms of this agent, we believe we may be offering novel approaches towards addressing these terrible conditions.”
“Treatment of chronic neurodegenerative conditions require a multi-factorial approach that addresses various molecular pathologies involved in the condition,” added Tim Dixon, CEO of Therapeutic Solutions International. “By providing novel formulations capable of augmenting delivery of agents across the blood brain barrier, we aim to provide physicians new tools in their arsenal in treatment of conditions such as multiple sclerosis, Alzheimer’s and post-stroke recovery.”
About Therapeutic Solutions International, Inc.
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
1 Dietrich et al. Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. J Neuroinflammation. 2018 Mar 7;15(1):71. https://www.ncbi.nlm.nih.gov/pubmed/29514678
2 Khalili et al. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial. Electron Physician. 2017 Jul 25;9(7):4899-4905. https://www.ncbi.nlm.nih.gov/pubmed/28894553
3 Wang et al. The Role of Alpha-Lipoic Acid in the Pathomechanism of Acute Ischemic Stroke. Cell Physiol Biochem. 2018 Jul 11;48(1):42-53. https://www.ncbi.nlm.nih.gov/pubmed/29996116
4 Choi et al. Alpha-lipoic acid treatment is neurorestorative and promotes functional recovery after stroke in rats.Mol Brain. 2015 Feb 11;8:9. https://www.ncbi.nlm.nih.gov/pubmed/25761600
5 Hager et al. Alpha-lipoic acid as a new treatment option for Alzheimer’s disease–a 48 months follow-up analysis. J Neural Transm Suppl. 2007;(72):189-93. https://www.ncbi.nlm.nih.gov/pubmed/17982894
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Therapeutic Solutions International, Inc.